Cyclacel Pharmaceuticals Acquires Key Cancer Drug Assets Cyclacel Pharmaceuticals has finalized the acquisition of Plogosertib-related assets for £250,000. These assets include patents for the PLK 1 inhibitor, targeting esophageal cancer and leukemia. This strategic move follows the liquidation of its UK subsidiary, Cyclacel Limited, and aligns with its focus on cancer therapeutics.12